Research And Markets Research And Markets
0 CHECKOUT

Low Back Pain - Pipeline Review, H1 2015

  • ID: 3308785
  • June 2015
  • 101 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Aestus Therapeutics, Inc.
  • Eisai Co., Ltd.
  • Grunenthal GmbH
  • MEDRx Co., Ltd.
  • Mesoblast Limited
  • Paladin Labs Inc.
  • MORE

Low Back Pain - Pipeline Review, H1 2015

Summary

This, ‘Low Back Pain - Pipeline Review, H1 2015’, provides an overview of the Low Back Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aestus Therapeutics, Inc.
  • Eisai Co., Ltd.
  • Grunenthal GmbH
  • MEDRx Co., Ltd.
  • Mesoblast Limited
  • Paladin Labs Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Low Back Pain Overview
Therapeutics Development
Pipeline Products for Low Back Pain - Overview
Pipeline Products for Low Back Pain - Comparative Analysis
Low Back Pain - Therapeutics under Development by Companies
Low Back Pain - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Low Back Pain - Products under Development by Companies
Low Back Pain - Companies Involved in Therapeutics Development
Aestus Therapeutics, Inc.
Astellas Pharma Inc.
Collegium Pharmaceutical, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Frontier Biotechnologies Co., Ltd
Grunenthal GmbH
Ipsen S.A.
MEDRx Co., Ltd.
Merck & Co., Inc.
Mesoblast Limited
Nektar Therapeutics
Pacira Pharmaceuticals, Inc.
Paladin Labs Inc.
Pfizer Inc.
Stayble Therapeutics
Teikoku Pharma USA, Inc.
Low Back Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(acetaminophen + tramadol hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(diclofenac sodium + eperisone) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(etodolac + lidocaine) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(etoricoxib + tizanidine) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(oxycodone hydrochloride + naltrexone) ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AB-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
abobotulinumtoxin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP-7962 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atx09-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bupivacaine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cebranopadol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Chronic Low Back Pain - Drug Profile
Product Description
Mechanism of Action
R&D Progress
duloxetine hydrochloride DR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eperisone SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
flurbiprofen sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MPC-06ID - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NKTR-181 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oxycodone hydrochloride ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-06372865 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Low Back Pain - Recent Pipeline Updates
Low Back Pain - Dormant Projects
Low Back Pain - Discontinued Products
Low Back Pain - Product Development Milestones
Featured News & Press Releases
Apr 07, 2015: Mesoblast Phase 3 Program For Degenerative Disc Disease To Include European Sites After Positive Meeting With European Medicines Agency
Feb 25, 2015: Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain
Jan 14, 2015: Mesoblast Reports Positive 24 Month Results in Phase 2 Trial for Chronic Low Back Pain and Initiation of Phase 3 Program at JP Morgan Healthcare Conference
Nov 13, 2014: Mesoblast's Phase 2 Trial Results In Chronic Low Back Pain Presented at North American Spine Society Annual Meeting
Apr 02, 2014: Collegium Pharmaceutical Announces Positive Topline Results of Clinical Study Evaluating the Effect of Crushing Oxycodone DETERx Compared with OxyContin
Mar 19, 2014: Collegium Pharmaceutical Announces Allowance of New Claims Covering DETERx, an Abuse-Deterrent, Extended-Release, Technology Platform
Feb 04, 2014: Collegium Pharmaceutical Announces Completion of Enrollment in Pivotal Phase 3 Clinical Study for Oxycodone DETERx, its Lead Abuse-Deterrent Development Program
Jan 23, 2014: Pfizer Reports Top-Line Results From ALO-02 Phase 3 Study
Oct 17, 2013: Collegium Pharmaceutical Announces Issuance of U.S. Patent and Allowance of New Claims Covering Oxycodone DETERx, an Abuse-Deterrent, Extended-Release Opioid Product
Apr 22, 2013: Mesoblast Reports Positive Interim Results In Phase II Trial Of Adult Stem Cells For Intervertebral Disc Repair
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Low Back Pain, H1 2015
Number of Products under Development for Low Back Pain - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Low Back Pain - Pipeline by Aestus Therapeutics, Inc., H1 2015
Low Back Pain - Pipeline by Astellas Pharma Inc., H1 2015
Low Back Pain - Pipeline by Collegium Pharmaceutical, Inc., H1 2015
Low Back Pain - Pipeline by Eisai Co., Ltd., H1 2015
Low Back Pain - Pipeline by Eli Lilly and Company, H1 2015
Low Back Pain - Pipeline by Frontier Biotechnologies Co., Ltd, H1 2015
Low Back Pain - Pipeline by Grunenthal GmbH, H1 2015
Low Back Pain - Pipeline by Ipsen S.A., H1 2015
Low Back Pain - Pipeline by MEDRx Co., Ltd., H1 2015
Low Back Pain - Pipeline by Merck & Co., Inc., H1 2015
Low Back Pain - Pipeline by Mesoblast Limited, H1 2015
Low Back Pain - Pipeline by Nektar Therapeutics, H1 2015
Low Back Pain - Pipeline by Pacira Pharmaceuticals, Inc., H1 2015
Low Back Pain - Pipeline by Paladin Labs Inc., H1 2015
Low Back Pain - Pipeline by Pfizer Inc., H1 2015
Low Back Pain - Pipeline by Stayble Therapeutics, H1 2015
Low Back Pain - Pipeline by Teikoku Pharma USA, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Low Back Pain Therapeutics - Recent Pipeline Updates, H1 2015
Low Back Pain - Dormant Projects, H1 2015
Low Back Pain - Dormant Projects (Contd..1), H1 2015
Low Back Pain - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Low Back Pain, H1 2015
Number of Products under Development for Low Back Pain - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Aestus Therapeutics, Inc.
Astellas Pharma Inc.
Collegium Pharmaceutical, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Frontier Biotechnologies Co., Ltd
Grunenthal GmbH
Ipsen S.A.
MEDRx Co., Ltd.
Merck & Co., Inc.
Mesoblast Limited
Nektar Therapeutics
Pacira Pharmaceuticals, Inc.
Paladin Labs Inc.
Pfizer Inc.
Stayble Therapeutics
Teikoku Pharma USA, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

RELATED PRODUCTS from Db